Nutri/System using Prozac/phentermine combo in place of "phen/fen" for obesity; Jenny Craig ends Rx use.
Executive Summary
PROZAC5/PHENTERMINE TO REPLACE "FEN/PHEN" AT NUTRI/SYSTEM centers offering pharmacologic therapy for obesity, the weight loss center company said. The decision follows another round of negative publicity for the unapproved fenfluramine/phentermine combination and the approved fenfluramine isomer dexfenfluramine, sold as Redux by Wyeth-Ayerst and Interneuron. Lilly's Prozac (fluoxetine) and fenfluramine both affect serotonin levels in the brain; however, fluoxetine is a selective serotonin reuptake inhibitor, while fenfluramine is a serotonin reuptake inhibitor and releasing agent.You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: